アルブミンの市場規模、シェア、成長分析：タイプ別、用途別、販売チャネル別、エンドユーザー別、地域別 - 産業予測 2025～2032年

アルブミン市場規模は2023年に66億9,000万米ドルと評価され、2024年の70億8,000万米ドルから2032年には112億1,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは5.9％で成長する見通しです。

アルブミンの世界市場は、血液量の増加、肝疾患の治療、火傷の管理といった重要な医療用途により、大きな成長が見込まれています。浸透圧の維持や必須物質の輸送といったアルブミンの主な機能が、その治療の可能性を高めています。促進要因としては、生命を脅かす疾患の有病率の上昇、外科手術の増加（2022年には世界で3億1,000万件の手術が行われた）、非治療用途の増加などが挙げられます。Grifolsの肝硬変に対するアルブテインの評価や、Shilpa Biologicalsの環境に優しい組換えヒトアルブミンのような革新的な進歩は、より効果的で持続可能な製品へのシフトを示唆しています。ワクチン製剤を改良するためのアルブメディックスとバルネバのようなコラボレーションは、ヘルスケアソリューションを前進させ、必要不可欠な治療への世界のアクセスを高めるという業界のコミットメントを表しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢

アルブミン市場規模：タイプ別

• 市場概要
• ヒト血清アルブミン
• 牛血清アルブミン
• 組み換えアルブミン

アルブミン市場規模：用途別

• 市場概要
• 治療薬
• 医薬品の処方とワクチン
• メディアの構成要素
• その他の用途

アルブミン市場規模：販売チャネル別

• 市場概要
• 企業対消費者（B2C）
• 企業間取引（B2B）

アルブミン市場規模：エンドユーザー別

• 市場概要
• 病院と診療所
• 製薬・バイオテクノロジー企業
• 調査機関

アルブミン市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Merck KGaA（Germany）
• CSL Limited（Australia）
• Grifols S.A.（Spain）
• Baxter International Inc.（USA）
• China Biologic Products Holdings, Inc.（China）
• Takeda Pharmaceuticals（Japan）
• Octapharma AG（Switzerland）
• Novozymes A/S（Denmark）
• Thermo Fisher Scientific Inc.（USA）
• Ventria Bioscience（USA）
• Albumedix Ltd.（UK）
• Biotest AG（Germany）
• HiMedia Laboratories（India）
• Invitria（USA）
• Medxbio Pte Ltd.（Singapore）
• RayBiotech, Inc.（USA）
• SeraCare（USA）
• Kedrion S.p.A.（Italy）
• Albumin Therapeutics, LLC（USA）

結論と提言

Albumin Market size was valued at USD 6.69 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 11.21 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The global albumin market is poised for significant growth due to its critical medical applications in increasing blood volume, treating liver diseases, and managing burn injuries. Key functions of albumin, such as maintaining osmotic pressure and transporting essential substances, enhance its therapeutic potential. Driving factors include the rising prevalence of life-threatening diseases, an increase in surgical procedures-310 million surgeries were performed globally in 2022-and an uptick in non-therapeutic uses. Innovative advancements, like Grifols' evaluation of Albutein for cirrhosis, and Shilpa Biologicals' environmentally friendly recombinant Human Albumin, signal a shift towards more effective and sustainable products. Collaborations, like that of Albumedix with Valneva to improve vaccine formulations, represent the industry's commitment to advancing healthcare solutions and boosting global access to essential treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Albumin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Albumin Market Segments Analysis

Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Albumin Market

The albumin market is driven by several key factors, notably the rising demand for albumin in regenerative medicine, vaccine stabilization, and drug formulations. Its significance in contemporary biopharmaceuticals is highlighted by its applications in plasma expansion, drug delivery systems, and nanomedicine. Additionally, the increasing prevalence of chronic diseases, including conditions such as hypovolemia and liver disorders, is prompting pharmaceutical companies to innovate and develop new therapeutic drugs. This growing patient population necessitates advanced treatments, further stimulating the demand for albumin and enhancing its role as a crucial component in various medical applications and drug formulations.

Restraints in the Albumin Market

The albumin market faces significant challenges due to the intricate and costly production processes, particularly for recombinant albumin. The extensive reliance on plasma collection results in complexities surrounding purification and quality control for plasma-derived albumin. Additionally, the operational costs are heightened by fluctuations in plasma supply, stringent regulatory approval processes, and the necessity for cold-chain logistics. These factors collectively impede accessibility and affordability, particularly in developing regions, ultimately acting as major restraints on the albumin market's growth and expansion potential, affecting both manufacturers and end-users alike.

Market Trends of the Albumin Market

The albumin market is experiencing a notable shift towards sustainable production methods, with a growing emphasis on recombinant albumin. Concerns surrounding plasma sourcing, potential pathogen transmission, and supply chain vulnerabilities are driving companies to invest in genetic engineering technologies. This transition is yielding innovative alternatives, including plant-based and yeast-expressed recombinant albumin, which promise enhanced safety and environmental sustainability. As the industry pivots away from traditional plasma-derived products, these advancements not only address contamination risks but also offer cost-effective solutions that appeal to both manufacturers and consumers. This trend underscores a broader commitment to safety and sustainability in biopharmaceutical manufacturing.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Albumin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Global Albumin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Drug Formulation and Vaccines
• Component of Media
• Other Applications

Global Albumin Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Business-To-Consumer (B2C)
• Business-To-Business (B2B)

Global Albumin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Global Albumin Market Size & CAGR (2025-2032)

• North America (Type, Application, Sales Channel, End-User)
  • US
  • Canada
• Europe (Type, Application, Sales Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Sales Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Sales Channel, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Sales Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novozymes A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ventria Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumedix Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HiMedia Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitria (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medxbio Pte Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SeraCare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumin Therapeutics, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations